CHOP and COG Will Validate New Tool to Measure NF1-Related Progressive Vision Loss
Jul 15, 2021
CHOP researchers will use optical coherence tomography (OCT) to measure vision changes associated with NF1-related optic pathway gliomas.
Your child will be cared for by one of the most accomplished teams of childhood cancer experts in the world. We provide medical care, emotional counseling and much more. We make sure your child, you and every family member get the highest level of support.
Jul 15, 2021
CHOP researchers will use optical coherence tomography (OCT) to measure vision changes associated with NF1-related optic pathway gliomas.
Jul 1, 2021
The Division of Oncology at Children’s Hospital of Philadelphia (CHOP) has appointed Sarah Tasian, MD, as Chief of the Section of Hematologic Malignancies.
Jun 28, 2021
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
Jun 1, 2021
On May 28, Dr. Stephan Grupp was featured on The Doctors to discuss the latest in CAR-T cell therapy and how it is changing the future of cancer care.
May 12, 2021
CHOP researchers were interviewed as a part of a comprehensive article about cell and gene therapy in Philadelphia Magazine.
May 10, 2021
CHOP researchers have found that MN1 overexpression leads to stabilization of the BAF complex, which leads to overproduction of progenitor and stem cells.
Apr 20, 2021
Grant awarded to CHOP and collaborating institutions will fund research into identifying and treating slowly progressive neuroblastoma, which currently lacks treatment options.
Apr 9, 2021
The award was presented to the St. Baldrick’s Foundation-Stand Up 2 Cancer Pediatric Cancer Dream Team, co-led by CHOP, at the annual AACR conference.
Mar 29, 2021
Established in 2015, the Evan Lindberg Neuroblastoma Research Scholars Program supports exceptional early-career scientists at CHOP who are dedicated to finding a cure for neuroblastoma.
Mar 16, 2021
CHOP researchers will receive funds to discover a new drug that targets MYCN, a transcription factor involved in some pediatric cancers.